During the past decade, Division of Kidney Diseases and Hypertension conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Division of Kidney Diseases and Hypertension" are "ADPKD" (1 trials), "Autosomal Dominant Polycystic Kidney" (1 trials) and "Chronic Kidney Disease" (1 trials). Many other conditions were trialed in "Division of Kidney Diseases and Hypertension" in a lesser frequency.

Most popular intervention types in "Division of Kidney Diseases and Hypertension" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bardoxolone methyl oral capsule" (1 trials), "Countdown to fistula program" (1 trials), "Daily weight measurement and monitoring" (1 trials), "Education" (1 trials) and "Focused advanced directive program" (1 trials). Other intervention names were less common.

The vast majority of trials in "Division of Kidney Diseases and Hypertension" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Division of Kidney Diseases and Hypertension". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Division of Kidney Diseases and Hypertension, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Division of Kidney Diseases and Hypertension, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".